Evidence map›Paper›PMID 40430853›Full record

ArticlePharmaceutics2025

Physiologically Based Pharmacokinetic Modeling of Biologic Case Studies in Monkeys and Humans Reveals the Necessity of an Additional Clearance Term.

Felix Stader, Pradeep Sharma, Weize Huang, Mary P Choules, Marie-Emilie Willemin, Xinwen Zhang, Estelle Yau, Abdallah Derbalah, Adriana Zyla, Cong Liu and 1 more

Abstract read
In one paragraph

Article in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Felix StaderCertara Predictive Technologies, Certara UK Ltd., Sheffield S1 2BJ, UK.ORCID 0000-0002-4223-6754
Pradeep SharmaClinical Pharmacology and Quantitative Pharmacology, Biopharmaceuticals R&D, AstraZeneca, Cambridge CB1 9JS, UK.ORCID 0000-0003-3415-8917
Weize HuangGenentech Inc., South San Francisco, CA 94404, USA.
Mary P ChoulesAstellas Pharma Global Inc., Northbrook, IL 60062, USA.ORCID 0000-0003-1771-3245
Marie-Emilie WilleminJohnson & Johnson, 2340 Beerse, Belgium.ORCID 0000-0002-1974-1170
Xinwen ZhangAmgen Inc., South San Francisco, CA 94080, USA.
Estelle YauSanofi R&D, 94403 Vitry-sur-Seine, France.ORCID 0000-0001-8323-5080
Abdallah DerbalahCertara Predictive Technologies, Certara UK Ltd., Sheffield S1 2BJ, UK.ORCID 0000-0003-1841-9646
Adriana ZylaCertara Predictive Technologies, Certara UK Ltd., Sheffield S1 2BJ, UK.
Cong LiuCertara Predictive Technologies, Certara UK Ltd., Sheffield S1 2BJ, UK.
Armin SeppCertara Predictive Technologies, Certara UK Ltd., Sheffield S1 2BJ, UK.ORCID 0000-0002-9276-5814

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

antibody–drug conjugatebispecific antibodymonoclonal antibodyphysiologically based pharmacokinetic modeltranslational study

Identifiers

PMID40430853
PMCPMC12115253

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.